{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:47:56Z","timestamp":1785880076461,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["BYKY-CX2023017"],"award-info":[{"award-number":["BYKY-CX2023017"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["BYKY-CX2024009"],"award-info":[{"award-number":["BYKY-CX2024009"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijid.2026.108809","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:16:19Z","timestamp":1779376579000},"page":"108809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam for the treatment of infections caused by drug-resistant Pseudomonas aeruginosa: an updated systematic review and meta-analysis based on adjusted data from observational studies"],"prefix":"10.1016","volume":"169","author":[{"given":"Pengfei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoni","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108809_bib0001","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00134-013-2828-9","article-title":"Clinical outcomes of pseudomonas aeruginosa pneumonia in intensive care unit patients","volume":"39","author":"Tumbarello","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2026.108809_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2026.108809_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ijid.2026.108809_bib0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Collaborators","year":"2022","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.ijid.2026.108809_bib0006","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0007","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/antibiotics13070629","article-title":"Novel antibiotics for gram-negative nosocomial pneumonia","volume":"13","author":"Almyroudi","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijid.2026.108809_bib0008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2026.108809_bib0009","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0012","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 \u00d7 \u201920 progress\u2014development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0014","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2026.108809_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijid.2026.108809_bib0016","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2026.108809_bib0018","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0020","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0021","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jac\/dkab494","article-title":"Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, phase 3 trial comparing ceftolozane\/tazobactam and meropenem for treatment of hospital-acquired\/ventilator-associated bacterial pneumonia","volume":"77","author":"Martin-Loeches","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0022","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0023","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0024","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijid.2026.108809_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/INF.0000000000003832","article-title":"Safety and efficacy of ceftolozane\/tazobactam versus meropenem in neonates and children with complicated urinary tract infection, including pyelonephritis: a phase 2, randomized clinical trial","volume":"42","author":"Roilides","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2026.108809_bib0026","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0027","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.1359","article-title":"1729. Real-world experience with ceftazidime-avibactam compared with ceftolozane-tazobactam on clinical outcomes in pseudomonas aeruginosa infections","volume":"9","author":"Golia","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0029","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s42770-023-01193-x","article-title":"Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime\/avibactam and ceftolozane\/tazobactam","volume":"55","author":"Neves","year":"2024","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.ijid.2026.108809_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0031","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3390\/antibiotics13080699","article-title":"Clinical outcomes of ceftazidime\u2013avibactam versus ceftolozane\u2013tazobactam in managing pseudomonal infections in patients undergoing renal replacement therapy","volume":"13","author":"El Nekidy","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijid.2026.108809_bib0032","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/jac\/dkae313","article-title":"Comparative evaluation of early treatment with ceftolozane\/tazobactam versus ceftazidime\/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant pseudomonas aeruginosa","volume":"79","author":"Lodise","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0033","article-title":"Impact of antimicrobial therapy on mortality and readmission in multidrug-resistant pseudomonas infections: a retrospective study at Dammam medical complex","volume":"16","author":"Alsaeed","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ijid.2026.108809_bib0034","article-title":"Effectiveness of ceftazidime\u2013avibactam versus ceftolozane\u2013tazobactam for multidrug-resistant pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","author":"Shields","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cid\/ciae332","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant pseudomonas aeruginosa bacteremia or pneumonia","volume":"80","author":"Shah","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"Supplement_2","key":"10.1016\/j.ijid.2026.108809_bib0036","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.115","article-title":"1649. Ceftolozane-tazobactam or ceftazidime-avibactam versus best available therapy in the treatment of difficult-to-treat Pseudomonas aeruginosa infections: a retrospective comparative effectiveness analysis of 195 U.S. hospitals, 2016\u20132020","volume":"9","author":"Lawandi","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0037","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against multidrug-resistant isolates of Escherichia coli, klebsiella pneumoniae, and pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108809_bib0038","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00189-22","article-title":"In vitro activity of ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators against pseudomonas aeruginosa isolates collected in united states hospitals according to results from the SMART surveillance program, 2018 to 2020","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0039","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jac\/dkaa049","article-title":"Lung penetration, bronchopulmonary pharmacokinetic\/pharmacodynamic profile and safety of 3 g of ceftolozane\/tazobactam administered to ventilated, critically ill patients with pneumonia","volume":"75","author":"Caro","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jac\/dkad367","article-title":"Therapeutic drug monitoring of ceftazidime\/avibactam: why one leg is not enough to run","volume":"79","author":"Gatti","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0041","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108809_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02312-24","article-title":"Mutations leading to ceftolozane\/tazobactam and imipenem\/cilastatin\/relebactam resistance during in vivo exposure to ceftazidime\/avibactam in pseudomonas aeruginosa","volume":"13","author":"Rapsinski","year":"2025","journal-title":"Microbiol Spectrum"},{"key":"10.1016\/j.ijid.2026.108809_bib0043","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of pseudomonas aeruginosa high-risk clones","volume":"21-22","author":"Oliver","year":"2015","journal-title":"Drug Resist Updat"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:08:21Z","timestamp":1785877701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226004443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S1201971226004443"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108809","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam for the treatment of infections caused by drug-resistant Pseudomonas aeruginosa: an updated systematic review and meta-analysis based on adjusted data from observational studies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108809"}}